|Articles|February 1, 1997

Firm offers health check on the Web

Greenstone Healthcare Solutions, the Kalamazoo, MI-based disease management subsidiary of Pharmacia & Upjohn, launched a free, confidential health-risk assessment on the World Wide Web.

Greenstone Healthcare Solutions, the Kalamazoo, MI-based disease management subsidiary of Pharmacia & Upjohn, launched a free, confidential health-risk assessment on the World Wide Web.

The You First™ Health Risk Assessment uses a browser's answers to questions about family history, health habits and lifestyle behaviors to create a personal report that includes recommendations to improve health and minimize potential problems. Through statistical analysis, a person's lifestyle risks, such as smoking, obesity and not wearing seat belts, are evaluated against documented outcomes associated with those risks.

Respondents receive a report that uses charts and graphs to depict their overall health risk along a continuum from "very low" risk to "very high." The questionnaire takes about five minutes to complete and is located at http://www.youfirst.com.

Greenstone will customize access to its health risk assessment for MultiPlan Inc., a preferred provider organization with more than 20 million lives in the United States. The company also plans to sell the product as an on-line product or in printed format to other organizations.

Information on Greenstone and disease management is located at the company's Web site at http://www.ghsnet.com. PR


Related to this article

Pharmaceutical Executive Daily
FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance.
Former U.S. Representative Joe Cunningham (D-SC), spokesperson, Pharmaceutical Reform Alliance. dismisses the pharmaceutical industry's innovation argument against MFN pricing.